IP Library › Granted Patent US 11,254,736
Granted Patent B2
US 11,254,736 · App. 16/789,626 · Granted Feb 22, 2022

Antibodies comprising a common light chain and uses thereof

Inventors: Thomas Charpentier (Philadelphia, PA); Ross Chambers (Philadelphia, PA); Lewis J. Stafford (Philadelphia, PA); Trevor Barnes (Philadelphia, PA); Jonathan T. Sullivan (Philadelphia, PA)
Assignee: INTEGRAL MOLECULAR, INC.
C07K16/18A61K38/00C07K2317/24C07K2317/565C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,254,736
App. No.
16/789,626
Granted
Feb 22, 2022
Kind
B2
Abstract

Peptides and uses thereof, such as a common light chain in an antibody, are provided.

Claims (30)

1. An antibody light chain variable region comprising a light chain CDR1 (LCDR1), CDR2 (LCDR2), and CDR3 (LCDR3), wherein the light chain variable region comprises:

a LCDR1 of SEQ ID NO: 19; a LCDR2 of SEQ ID NO: 21; and a LCDR3 of SEQ ID NO: 23;

a LCDR1 of SEQ ID NO: 58; a LCDR2 of SEQ ID NO: 60; and a LCDR3 of SEQ ID NO: 61;

a LCDR1 of SEQ ID NO: 63; a LCDR2 of SEQ ID NO: 64; and a LCDR3 of SEQ ID NO: 65;

a LCDR1 of SEQ ID NO: 66; a LCDR2 of SEQ ID NO: 67; and a LCDR3 of SEQ ID NO: 68;

a LCDR1 of SEQ ID NO: 84; a LCDR2 of SEQ ID NO: 64; and a LCDR3 of SEQ ID NO: 73;

a LCDR1 of SEQ ID NO: 49; a LCDR2 of SEQ ID NO: 77; and a LCDR3 of SEQ ID NO: 78; or

a LCDR1 of SEQ ID NO: 57; a LCDR2 of SEQ ID NO: 79; and a LCDR3 of SEQ ID NO: 80.

2. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises a LCDR1 of SEQ ID NO: 19; a LCDR2 of SEQ ID NO: 21; and a LCDR3 of SEQ ID NO: 23.

3. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1, the light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 19, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 21, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 23.

4. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1, the light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 19, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 21, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 23.

5. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 1.

6. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 2, the light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 19, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 21, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 23.

7. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2, the light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 19, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 21, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 23.

8. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2.

9. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises a LCDR1 of SEQ ID NO: 52; a LCDR2 of SEQ ID NO: 54; and a LCDR3 of SEQ ID NO: 56.

10. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 3, the light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 52, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 54, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 56.

11. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3, the light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 52, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 54, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 56.

12. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 3.

13. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 4, the light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 52, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 54, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 56.

14. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4, the light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 52, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 54, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 56.

15. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 4.

16. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises a LCDR1 of SEQ ID NO: 58; a LCDR2 of SEQ ID NO: 60; and a LCDR3 of SEQ ID NO: 61.

17. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises a LCDR1 of SEQ ID NO: 63; a LCDR2 of SEQ ID NO: 64; and a LCDR3 of SEQ ID NO: 65.

18. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises a LCDR1 of SEQ ID NO: 66; a LCDR2 of SEQ ID NO: 67; and a LCDR3 of SEQ ID NO: 68.

19. The antibody light chain variable region of claim 1 , wherein the light chain variable region comprises a LCDR1 of SEQ ID NO: 84; a LCDR2 of SEQ ID NO: 64; and a LCDR3 of SEQ ID NO: 73.

20. A nucleic acid molecule encoding the antibody light chain variable region of claim 1 .

21. A nucleic acid molecule encoding the antibody light chain variable region of claim 2 .

22. A nucleic acid molecule encoding the antibody light chain variable region of claim 9 .

23. A cell comprising the nucleic acid molecule of claim 20 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: CHARPENTIER, THOMAS; CHAMBERS, ROSS; STAFFORD, LEWIS; BARNES, TREVOR; SULLIVAN, JONATHAN
To: INTEGRAL MOLECULAR, INC.
Reel/Frame 055464/0324 →
Continuity (2)
Provisional Application 62806052 · Feb 15, 2019
Related Publication 20200262898A1 · Aug 20, 2020
Cited By (1)
US 12,428,474